Full-Time

MGBCI Ambulatory Solid Tumor Oncology NP

Mass General Brigham

Mass General Brigham

1-10 employees

Early-stage life science venture investor

Compensation Overview

$50.70 - $134.78/hr

+ Differentials + Premiums + Bonuses

Boston, MA, USA

In Person

Master's, PhD

Category
Medical, Clinical & Veterinary (1)
Required Skills
Epic (EHR)
Electronic Health Records (EHR)

Get referred to Mass General Brigham

See people who can refer or advise you

Requirements
  • Satisfactory completion of an approved formal education program preparing professional nurses to practice as nurse practitioners.
  • ANA or other appropriate nursing certification in the area of practice and authorization by the Massachusetts Board of Registration in Nursing to practice in the expanded role.
  • A Master of Science in Nursing, Doctor of Nursing Practice, or PhD degree in Nursing is required; experience cannot substitute for the degree.
  • Completion of a Master's or post-master's degree in an adult program accredited by the Commission on Collegiate Nursing Education or the National League for Nursing Accrediting Commission.
  • Current Adult/Gerontology Nurse Practitioner or Family Nurse Practitioner certification by an accredited advanced practice registered nurse certifying body is required.
  • DEA registration and a current advanced practice registered nurse license to practice in Massachusetts are required.
  • At least 2 years of current nurse practitioner experience caring for an oncology-focused patient population is required.
  • Proficiency with Epic electronic medical records.
  • Experience with telemedicine.
  • Ability to provide and direct feedback and guidance to staff.
  • Ability to function effectively in a fast-paced environment and maintain attention to detail.
  • Expert clinical judgment skills to function independently.
  • Ability to collaborate with patients, families, staff, and community health workers.
  • Ability to work under frequent stress in busy clinical settings and changing organizational conditions.
  • Ability to work independently, demonstrate initiative, and use problem-solving and conflict-resolution skills.
Responsibilities
  • Provide direct care, counseling, and teaching to a selected patient population.
  • Perform physical examinations and preventive health measures appropriate to patient needs.
  • Order, interpret, and evaluate laboratory and diagnostic tests.
  • Arrange patient care plans and follow-up based on diagnostic, laboratory, and physical assessment findings.
  • Perform appropriate laboratory tests for the specific patient population.
  • Order medications and write prescriptions according to organizational and regulatory policies and procedures.
  • Document pertinent patient-care findings in the medical record.
  • Set priorities for efficient, cost-effective management of patient care, resources, supplies, and equipment.
  • Communicate patient data with physicians and other health care professionals as part of an interdisciplinary care approach.
  • Provide patient education and counseling focused on health maintenance, prevention, and promotion.
  • Assist staff, patients, and families in using community resources.
  • Develop, implement, and revise nurse practitioner guidelines and prescription-writing monitoring requirements with the designated physician and nursing leadership.
  • Evaluate patient-care outcomes and revise care plans as necessary.
  • Provide and obtain consultative services as required.
  • Participate in departmental and organizational quality-improvement programs and use quality-improvement data and research findings to enhance care.
  • Collaborate with providers within the institution and community.
  • Serve on nursing and hospital committees and communicate information to staff.
  • Participate in productivity metrics and cost-effective management of personnel, time, supplies, and equipment.
  • Collaborate with nursing and practice leadership on staffing patterns for clinical areas.
  • Participate in employee selection processes when requested and provide input into staff evaluations as appropriate.
  • Precept nursing students and staff, participate in new-staff orientation, and contribute to continuing-education programs.
  • Educate professional and lay groups through lectures, papers, publications, and educational materials.
  • Develop annual objectives, complete annual credentialing, and assist with clinical-area goals and objectives.
  • Maintain current knowledge of legislation affecting health care delivery.
  • Integrate patient-population and disease-state needs into programmatic goals and objectives.
  • Participate in nursing research and grant writing as appropriate and review relevant research publications.
  • Provide comprehensive ambulatory care to solid-tumor medical oncology patient populations.
  • Perform comprehensive histories and physical examinations and complete timely clinical documentation.
  • Participate in scheduled encounters and provide urgent evaluation and management for complex symptoms and newly diagnosed hematology-oncology patients.
  • Coordinate diagnostic procedures and related radiology and clinic appointments, communicate test results, and provide team coverage.
  • Perform or oversee specialized procedures for the medical oncology population as agreed with the collaborating physician.
  • Follow and co-manage patients with the physician across the illness trajectory.
  • Facilitate patient movement through the health system and efficient use of resources through interdepartmental collaboration.
  • Coordinate communications among physicians, patients, families, and staff.
  • Order standard-of-care antineoplastics and oncologic investigational new drugs and write prescriptions in accordance with organizational and regulatory policies.
  • Participate in research efforts, professional development, teaching, committees, and quality and safety initiatives.
  • Maintain clinical knowledge and skills based on current health care practice and research and satisfy position and licensure education requirements.
  • May provide direction to designated personnel.
Desired Qualifications
  • Clinical Nurse Practitioner experience in an ambulatory practice managing an oncology-focused patient population is strongly preferred.
  • Oncology Nursing Board Certification is strongly preferred.
  • Proficiency with Epic and electronic medical records is strongly preferred.
  • Experience with EPIC InBasket management and telemedicine is strongly preferred.
  • Familiarity with clinical trials is strongly preferred.

Mass General Brigham Ventures funds early-stage life science ideas arising from Mass General Brigham’s research network. It provides first access to deal flow and proprietary rights, backing the formation and growth of new companies and technologies. It uses capital and support to help translate bold innovations into drugs and medical technologies that improve patient outcomes worldwide.

Company Size

1-10

Company Stage

N/A

Total Funding

$1.9B

Headquarters

Cambridge, Massachusetts

Founded

2008

Get referred to Mass General Brigham

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Abcuro raised $66 million on 2026-08-18 with MGB Ventures backing ulviprubart.
  • MGB keeps attracting 2026 external partners, including Keros’s March ALS MyMatch collaboration.
  • The 2026 cancer institute buildout and ongoing research pipeline deepen future venture formation opportunities.

What critics are saying

  • On 2026-07-08, 4,000 Brigham nurses struck and MGB locked them out five days.
  • On 2026-04-29, nurses protested service closures and a $35.9 million FY2024 executive compensation pool.
  • The 2028 Dana-Farber split and $1.9 billion Ragon buildout raise capital pressure and execution risk.

What makes Mass General Brigham unique

  • 2026-08-16 strategy still gives MGB Ventures first access to internal seed and Series A IP.
  • MGB’s clinical network supplies trial sites, physician inventors, and commercialization support across the system.
  • The 2026 investment model combines venture capital with company-building through translational acceleration and Ignite programs.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Flexible Work Hours

Remote Work Options

Hybrid Work Options

Paid Vacation

Paid Sick Leave

Paid Holidays

Family Planning Benefits

Fertility Treatment Support

Professional Development Budget

Conference Attendance Budget

Wellness Program

Mental Health Support

Gym Membership

Phone/Internet Stipend

Home Office Stipend

Stock Options

Company Equity

401(k) Company Match

Parental Leave

Adoption Assistance

Childcare Support

Relocation Assistance

Employee Referral Bonus

Tuition Reimbursement

Professional Certification Support

Mentorship Program

Meal Benefits

Commuter Benefits

Legal Services

Employee Discounts

Company Social Events

Company News

ABCuro
Aug 18th, 2026
Abcuro announces $66 million Series D financing to advance its first-in-class Medicine in development for Inclusion Body Myositis.

Abcuro announces $66 million Series D financing to advance its first-in-class Medicine in development for Inclusion Body Myositis. * Proceeds to support a potentially registrational clinical study in less severe inclusion body myositis (IBM) patients expected to begin in Q4 2026 and report top line results in 2H 2028 * Ulviprubart showed a trend toward clinically meaningful slowing of disease progression in patients with less severe IBM in the previous Phase 2/3 MUSCLE study * Series D financing led by New Leaf Venture Partners, joined by Abcuro's existing investors and new investor Rock Springs Capital Newton, Massachusetts, August 18, 2026 - Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases through precise modulation of cytotoxic T cells, today announced the closing of a $66 million Series D financing led by current investor New Leaf Venture Partners with participation of existing investors including funds managed by abrdn Inc., Bain Capital Life Sciences, Samsara BioCapital, Redmile Group, Mass General Brigham Ventures, RA Capital Management, Pontifax, Sanofi Ventures, Foresite Capital, NEA, Eurofarma Ventures, Kaitai Capital, Soleus Capital, Nancy Chang, Shang Bay and joining the round is Rock Springs Capital. Proceeds from the Series D financing will support a new potentially registrational clinical study of ulviprubart, a first-in-class monoclonal antibody targeting killer cell lectin like receptor G1 (KLRG1), for the treatment of patients with less severe IBM. Abcuro has been in discussions with the U.S. Food and Drug Administration (FDA) and expects to initiate the new study in the fourth quarter of this year. Assuming positive results from the clinical study, Abcuro plans to file a biologics license application (BLA). "We are pleased to have this opportunity to further evaluate ulviprubart in patients with IBM, a devastating progressive disease," said Alex Martin, Chief Executive Officer of Abcuro. "We have begun preparations to initiate a clinical trial in the fourth quarter of 2026 as we continue our work to develop an effective treatment option in an indication where there is no approved therapy. We remain dedicated to the IBM community and thank our investors who share our conviction in ulviprubart's potential." Results from the recent Phase 2/3 MUSCLE study of ulviprubart in patients with IBM were presented at the 6th Global Conference on Myositis (GCOM) meeting in March 2026. The clinical data, while not statistically significant, showed a trend toward slowing of disease progression relative to placebo as measured by IBMFRS in the overall patient population, including a 50% slowing of disease progression in a pre-defined analysis of less severe IBM patients with IBMFRS >29. Ulviprubart was also shown to have a favorable safety and tolerability profile compared to placebo. "The MUSCLE study provided encouraging data in a pre-defined analysis of patients with less severe disease, underscoring ulviprubart's unique mechanism of targeting highly differentiated cytotoxic T cells expressing KLRG1," said Namita Goyal, MD, Chief of the Neuromuscular Division at the University of California, Irvine School of Medicine. "IBM continues to be a disabling, progressive disease with no approved treatment, affecting tens of thousands of patients around the world. Ulviprubart demonstrated clear and meaningful slowing of disease progression in less severe disease, offering real hope to patients, care partners, and the physicians who treat them." "There is a significant unmet need for an approved treatment for IBM. The expertise and persistence of the Abcuro team to understand this disease and the role ulviprubart may have in targeting these cytotoxic T cells that are associated with muscle destruction was key to our continued investment of the company. We are excited to work closely with the company as it moves forward in this next chapter," said Ron Hunt, Co-Founder and Managing Director of New Leaf Venture Partners. About Ulviprubart Ulviprubart is a first-in-class, potent, monoclonal antibody that targets pathogenic T cells that express killer cell lectin-like receptor G1 (KLRG1) on their cell surface, referred to as KLRG1+ T cells. Ulviprubart is designed to selectively target and deplete well-differentiated cytotoxic KLRG1+ T cells where KLRG1 is highly expressed, while sparing other immune cells, which may offer improvements in safety and tolerability as compared to other T cell depleting approaches. About Inclusion Body Myositis (IBM) IBM is a rare, debilitating and relentlessly progressive chronic autoimmune muscle disease with no approved pharmacologic treatments and a significant unmet need. It is mediated by highly differentiated T cells that are chronically or aberrantly overstimulated and can have detrimental long-term effects including destruction of healthy muscle tissue. People living with IBM progressively lose muscle function, including loss of grip, dexterity and mobility. Based on published epidemiology literature, the ICD-10 code for IBM and an estimate for those misdiagnosed or undiagnosed, Abcuro estimate there are approximately 40,000 patients diagnosed with IBM in the United States and Abcuro estimate the prevalence of IBM to be approximately 35,000 patients across major European countries and Japan. Abcuro estimate that patients with less severe disease represent nearly 50% of the overall IBM patient population. About Abcuro Abcuro is a clinical stage biotechnology company developing potentially first-in-class immunotherapies designed to benefit people living with debilitating and progressive rare autoimmune diseases and for other indications where certain cytotoxic T cells are pathogenic. Abcuro believe that by selectively targeting and depleting highly cytotoxic T cells, which are key drivers of chronic inflammation and damage, Abcuro can advance its mission to deliver potentially life-transforming, disease-modifying therapies to patients facing these devastating conditions. The company's lead program, ulviprubart, is currently being evaluated in inclusion body myositis (IBM). For more information, visit Abcuro on LinkedIn and at abcuro.com.

Claris Bio
Jul 29th, 2026
07-28-2026 Press Releases from Claris Bio

Latest Press Releases from Claris Bio.

Fierce Healthcare
Jun 15th, 2026
InStride Health lands $30M series C to expand pediatric mental health services

InStride Health, a provider of virtual specialty mental healthcare for children and young adults, has raised $30 million in Series C funding led by Echo Health Ventures and FMZ Ventures. Existing investors including .406 Ventures, General Catalyst and Mass General Brigham Ventures also participated. Founded in 2021, InStride offers insurance-based treatment for anxiety and obsessive-compulsive disorder in patients aged seven to 24. The company pairs each patient with a care team comprising a psychiatrist, therapist and exposure coach, providing support through text and a mobile application. InStride has treated 5,000 patients across 17 states, primarily on the East Coast and Texas. The company published data showing 97% of patients demonstrated clinical improvement, with a 53% average reduction in anxiety scores. The funding will support expansion into new markets and strengthen payer partnerships.

Associated Press
May 13th, 2026
Violet Therapeutics raises $4.75M to advance synaptic preservation therapy for neurodegenerative diseases

Violet Therapeutics, a biotechnology company developing therapies for neurodegenerative diseases, has raised $4.75 million in a seed extension round led by Lifespan Vision Ventures. Dementia Discovery Fund, UTEC, Ono Venture Investment and Mass General Brigham Ventures also participated. The Cambridge-based company will use the funding to advance its lead small molecule programme targeting EphB3 through IND-enabling activities. The therapy aims to halt and potentially reverse cognitive decline through glial-mediated synaptic preservation, addressing synaptic loss, the strongest predictor of cognitive decline in Alzheimer's and other neurodegenerative diseases. Violet's proprietary CONNECT platform maps cell-cell interaction networks to identify novel therapeutic targets. Founded by Mass General Brigham Ventures with researchers from Brigham and Women's Hospital, the company is developing first-in-class CNS therapies.

PR Newswire
Apr 23rd, 2026
Brigham nurses to picket as MGB executives earn $35.9M amid service closures and 0% wage offer

Registered nurses at Brigham and Women's Hospital will hold an informational picket on 29 April, protesting Mass General Brigham's corporate decisions affecting patient care and workforce conditions. The Massachusetts Nurses Association represents the nurses, who will demonstrate from 14:00 to 16:00 outside the hospital at 75 Francis Street, Boston. Nurses cite several service closures under MGB, including the Weiner Centre, Burn Unit and Integrated Care Management Programme. They criticise the health system's bargaining proposals, particularly a 0% wage offer for nurses below top step, whilst MGB reported a $59.2 million operating gain in 2025 and paid its top 14 executives $35.9 million in fiscal year 2024. The informational picket will not disrupt patient care, with nurses participating outside working hours.